Germinal centers are critical for affinity maturation of antibody (Ab) responses. This process allows the production of high-efficiency neutralizing Ab that protects against virus infection and bacterial exotoxins. In germinal centers, responding B cells selectively mutate the genes that encode their receptors for antigen. This process can change Ab affinity and specificity. The mutated cells that produce high-affinity Ab are selected to become Ab-forming or memory B cells, whereas cells that have lost affinity or acquired autoreactivity are eliminated. Normally, T cells are critical for germinal center formation and subsequent B cell selection. Both processes involve engagement of CD40 on B cells by T cells. This report describes how high-affinity B cells can be induced to form large germinal centers in response to (4-hydroxy-3-nitrophenyl) acetyl (NP)-Ficoll in the absence of T cells or signaling through CD40 or CD28. This requires extensive cross-linking of the B cell receptors, and a frequency of antigen-specific B cells of at least 1 in 1,000. These germinal centers abort dramatically at the time when mutated high-affinity B cells are normally selected by T cells. Thus, there is a fail-safe mechanism against autoreactivity, even in the event of thymus-independent germinal center formation.
Skip Nav Destination
Article navigation
7 February 2000
Article|
February 07 2000
Germinal Centers without T Cells
Carola García de Vinuesa,
Carola García de Vinuesa
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Search for other works by this author on:
Matthew C. Cook,
Matthew C. Cook
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Search for other works by this author on:
Jennifer Ball,
Jennifer Ball
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Search for other works by this author on:
Marion Drew,
Marion Drew
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Search for other works by this author on:
Yvonne Sunners,
Yvonne Sunners
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Search for other works by this author on:
Marilia Cascalho,
Marilia Cascalho
bDepartment of Microbiology and Immunology, University of California, San Francisco, California 94103-0670
Search for other works by this author on:
Matthias Wabl,
Matthias Wabl
bDepartment of Microbiology and Immunology, University of California, San Francisco, California 94103-0670
Search for other works by this author on:
Gerry G.B. Klaus,
Gerry G.B. Klaus
cDivision of Cellular Immunology, National Institute for Medical Research, London NW7 1AA, United Kingdom
Search for other works by this author on:
Ian C.M. MacLennan
Ian C.M. MacLennan
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Search for other works by this author on:
Carola García de Vinuesa
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Matthew C. Cook
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Jennifer Ball
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Marion Drew
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Yvonne Sunners
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Marilia Cascalho
bDepartment of Microbiology and Immunology, University of California, San Francisco, California 94103-0670
Matthias Wabl
bDepartment of Microbiology and Immunology, University of California, San Francisco, California 94103-0670
Gerry G.B. Klaus
cDivision of Cellular Immunology, National Institute for Medical Research, London NW7 1AA, United Kingdom
Ian C.M. MacLennan
aFrom the Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, United Kingdom
Abbreviations used in this paper: AP, alkaline phosphatase; BCR, B cell receptor; BrdU, 5-bromo-2′-deoxyuridine; CTLA-4, CTL antigen 4; Hγ1, human γ1; NP, (4-hydroxy-3-nitrophenyl)acetyl; PNA, peanut agglutinin; QM, quasimonoclonal; TdT, terminal deoxynucleotidyltransferase; TUNEL, TdT-mediated dUTP nick end labeling.
Received:
October 08 1999
Revision Requested:
November 17 1999
Accepted:
November 18 1999
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2000 The Rockefeller University Press
2000
The Rockefeller University Press
J Exp Med (2000) 191 (3): 485–494.
Article history
Received:
October 08 1999
Revision Requested:
November 17 1999
Accepted:
November 18 1999
Citation
Carola García de Vinuesa, Matthew C. Cook, Jennifer Ball, Marion Drew, Yvonne Sunners, Marilia Cascalho, Matthias Wabl, Gerry G.B. Klaus, Ian C.M. MacLennan; Germinal Centers without T Cells. J Exp Med 7 February 2000; 191 (3): 485–494. doi: https://doi.org/10.1084/jem.191.3.485
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement